Viewing Study NCT06604858

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:12 AM
Ignite Modification Date: 2026-03-15 @ 12:12 PM
Study NCT ID: NCT06604858
Status: RECRUITING
Last Update Posted: 2025-12-12
First Post: 2024-09-17
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer
Sponsor: MedSIR
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None Triple Negative Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Breast Cancer View
None Stage I Triple Negative Breast Cancer View
None Pembrolizumab View
None Carboplatin View
None Paclitaxel View